Background: Immunomodulatory therapies, including CTLA-4 and PD-1 inhibitors,
| INTRODUCTION
The field of cancer immunotherapy has seen many exciting developments recently, from the approval of new agents to the expansion of approved indications for existing agents. Research in the last decade has focused on a variety of ways to modulate the immune system to treat cancer. 1 Checkpoint inhibitors, which prevent T cell deactivation, have been particularly successful. However, by downregulating a host's immune system control mechanisms, novel side effects can occur that are distinct from the adverse effects associated with conventional chemotherapy. These events, known as immune-related adverse events (IRAEs), are thought to be secondary to the effects of autoimmunity induced by the lack of deactivation of auto-reactive T cells. Endocrine IRAEs such as hyperthyroidism, hypothyroidism, adrenal insufficiency, and hypophysitis were observed in several trials.
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Another class of immunomodulatory agents, PD-1 inhibitors, has been increasingly utilized, most notably pembrolizumab and nivolumab.
The KEYNOTE-002 trial demonstrated pembrolizumab's effectiveness in ipilimumab-refractory melanoma. 3 Later, the KEYNOTE-006 trial demonstrated the superiority of PD-1 inhibitors over ipilimumab, including improved progression-free survival and overall decreased mortality in advanced melanoma. 4 The combination of nivolumab and ipilimumab has also been utilized successfully, 5 with a concomitantly higher risk of adverse reactions compared to monotherapy. 6 Although noted to have a decreased overall rate of adverse events compared to CTLA-4 inhibitors, endocrinopathies were still observed during treatment with single agent pembrolizumab or nivolumab, including a higher incidence of hypothyroidism. 3, 7 In one series of 17 patients taking pembrolizumab, hypothyroidism (35%) and thyrotoxicosis (63%)
were the most common endocrine reactions reported.
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Checkpoint inhibitors are currently being used for a myriad of different cancers, including Merkel cell carcinoma, 8 renal cell carcinoma, 9 non-small cell lung cancer 10, 11 and squamous cell carcinoma of the head and neck. 12 They are also being studied for effectiveness in patients with other solid organ cancers. 3 Although previous existing literature has focused on immunomodulatory therapies in patients with metastatic melanoma, this study includes patients prescribed these drugs for any malignant indication at an urban academic tertiary-care institution, with several years of follow-up. Our goal is to provide a retrospective report of identified endocrine IRAEs associated with these increasingly utilized immunomodulatory therapies in a large cohort that includes patients with several years of follow-up.
| METHODS
We performed a retrospective analysis of all patients ≥18 years old who were prescribed ipilimumab, nivolumab and/or pembrolizumab 
| RESULTS
The study sample consisted of 388 patients (mean age:
62.7 ± 14.9 years, 56.4% men, 71.7% white) ( The row "Other" for the ethnicity data includes the responses "unknown" and "patient refused." The row "Hispanic or Latino" for the ethnicity data includes the responses "Hispanic or Latino," "Mexican/Mexican-American" and "Hispanic/Spanish origin." The row "Other" for the race data includes the responses "other," "unknown," "patient refused," "American Indian" and "multiple races."
two were also treated with testosterone. One patient had a history of prostate cancer so was not treated with testosterone to maintain suppression of his prostate-specific antigen (PSA). In addition, two of the seven patients underwent imaging studies, which were unremarkable for pituitary abnormalities. Immunomodulatory therapies were not discontinued in these patients for these reactions, although two patients did experience reactions of diarrhoea and lower extremity oedema that required cessation of therapy. A total of seven patients (1.8%) had evidence of hypopituitarism following administration of a checkpoint inhibitor, with a mean time to event of 16.71 ± 14.75 days.
No patients were found to have evidence of primary pancreatic or adrenal IRAEs.
| DISCUSSION
This study describes a 12.9% prevalence of endocrine abnormalities associated with the use of ipilimumab, nivolumab and/or pembrolizumab for any indication at a large, urban tertiary-care academic medical centre. We noted a predominance of thyroid-related in patients treated with ipilimumab alone to 39% in patients treated with a PD-1 inhibitor alone to 50% of patients who received both therapies.
T A B L E 2 Rates of endocrine immune-related adverse events (IRAEs) following immunomodulatory therapy
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Primary adrenal and pancreatic endocrinopathies due to immunomodulatory therapies have been uncommonly reported in the literature; similarly, none were found amount our cohort. Recent reports of adrenal insufficiency due to ipilimumab have ranged from 1% to 10%, although it is not always clear whether primary adrenal insufficiency is clearly differentiated from central adrenal insufficiency in these studies.
1 A meta-analysis of 191 reports found that pancreatitis occurred in 0.9% of 234 patients treated with ipilimumab and that primary adrenal insufficiency occurred in 1 case (0.4%).
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The present study did not describe any cases of adrenal and pancreatic IRAEs, which is slightly lower than or potentially consistent with the low rates of such events described in existing literature. This may in part be due to the retrospective nature of the study, without a proactive evaluation of patients for symptoms that would be in line with these reactions. The rates of overt pituitary and thyroid IRAEs, including hypothyroidism and thyrotoxicosis, fall within the ranges of previously reported findings. These findings indicate that previous reports of the frequency of endocrine IRAEs are likely reflective of the actual incidence and could provide realistic estimates of side effect profiles when counselling patients. In addition, we report a high incidence of subclinical hypothyroidism (5.4%), which is usually not documented in other reports.
This study is strengthened by the inclusion of a large cohort, as well as by our differentiation between primary and central causes of adrenal and thyroid dysfunction, which at times is difficult to distinguish in the existing literature.
The major limitation of this study is its retrospective nature.
Patients were not identified or followed prospectively, which made it difficult to determine the presence or severity of symptoms that may have prompted screening due to availability of documentation.
In particular, screening of thyroid function is performed routinely, but screening for other IRAEs including of the pituitary, pancreas and adrenal glands is usually prompted only by patient symptoms.
There may therefore be a lower rate of pituitary, pancreatic and adrenal IRAEs in our cohort than would be reported in a prospective study. Data on length of follow-up or discontinuation of immunomodulatory therapy were excluded because they were not always clearly noted in patient charts. Additionally, the retrospective nature of this study does not account for patients with pre-existing endocrine abnormalities that were only diagnosed after initiation of immunomodulatory therapy.
Other limitations include limitation of cohort size due to additional laboratory data and imaging studies that patients may have had obtained but that are not contained within our institution's data repository. Further, attributing reactions to particular drugs are complicated by the fact that some patients were prescribed more than one immunomodulatory therapy over the course of their treatment. In addition, it is difficult to assign a causal relationship between particular immunomodulatory therapy and an IRAE in a retrospective study; therefore, these data are also not reported.
The incidence, severity and duration of endocrine IRAEs vary, to the extent that some patients may be discontinued from their immunotherapy. Information about discontinuation of therapy was included when available; none of the overt thyroid reactions or pituitary reactions in our cohort specifically necessitated discontinuation of immunotherapy. However, the vast majority of IRAEs can be managed by correction of the endocrine dysfunction and/or monitoring of patient symptoms and laboratory values. Given the multidisciplinary nature of care required to achieve optimal outcomes, we urge for close coordination between oncologists and endocrinologists in the management of these complex patients.
In summary, our findings indicate that subclinical endocrine IRAEs may be more common than previously described. We recommend that clinicians be vigilant for signs and symptoms of such reactions when treating patients with immunomodulatory therapies and have a low threshold for initiating biochemical testing.
